The terms “single,” “dual,” and “triple agonist” come up constantly in metabolic peptide research. They describe how many receptors a compound activates — and that number has become a useful shorthand for a compound’s research profile. This explainer is for educational reference only.
What does “agonist” mean?
An agonist is a molecule that binds to a receptor and activates it. In incretin research, three receptors come up repeatedly: GLP-1, GIP, and glucagon. Each is involved in metabolic and glucose-regulation signaling.
Single, dual, and triple agonists
| Type | Receptors activated | Example compound |
|---|---|---|
| Single agonist | GLP-1 | Semaglutide |
| Dual agonist | GLP-1 + GIP | Tirzepatide |
| Triple agonist | GLP-1 + GIP + glucagon | Retatrutide |
Why add more receptors?
Each additional receptor target engages another arm of metabolic signaling. In published research, adding GIP (dual) and then glucagon (triple) activity has been associated with progressively larger effects in comparable models — which is why triple agonists like Retatrutide have drawn intense research interest.
Choosing a compound for research
The right compound depends on which receptor pathways a study is examining. For a deeper side-by-side, see our Retatrutide vs. Tirzepatide vs. Semaglutide comparison.
For laboratory and research use only. Not for human or animal consumption. This article summarizes publicly available research and is not medical advice.